Skip to main content

Table 2 Demographics of PAF and PsAF patients for circRNA expression validation and serum TGF-β1 level quantification

From: The potential regulatory role of hsa_circ_0004104 in the persistency of atrial fibrillation by promoting cardiac fibrosis via TGF-β pathway

 

PsAF (n = 30)

PAF (n = 30)

p value

Age, years

64 ± 9.46

63.67 ± 5.74

0.87

Male, n (%)

22 (73.3)

21(70)

0.774

BMI, kg/m2

27.28 ± 3.92

26.49 ± 4.07

0.452

Heart rate, bpm

88.77 ± 17.51

83.37 ± 23.88

0.322

CAD, n (%)

9 (30)

5 (16.7)

0.222

HTN, n (%)

18 (60)

20 (66.7%)

0.592

DM, n (%)

7 (23.3)

9 (30)

0.559

Smoke, n (%)

8 (26.7)

9 (30)

0.627

AF duration, months

14.3 ± 2.6

8.4 ± 2.9

0.056

LAD, mm

42.43 ± 4.35

40.72 ± 4.65

0.61

LVEF, %

63 ± 7.77

63.53 ± 7.46

0.787

LVEDD, mm

48.8 ± 4.05

49.2 ± 4.31

0.712

HbA1c, %

6.43 ± 1.02

5.81 ± 1.9

0.126

LDL, mmol/L

2.25 ± 0.84

2.56 ± 0.82

0.156

Creatine, µmol/L

74.15 ± 16.19

71.56 ± 17.13

0.55

BNP, pg/ml

1506.82 ± 719.46

1142.11 ± 782.98

0.185

β-blockers, n (%)

21 (70)

20 (66.7)

0.603

ACEI/ARB, n (%)

11 (36.7)

13 (43.3)

0.511

hsa_circ_0004104

0.6 ± 0.33

1.46 ± 0.41

 < 0.001

TGF-β1, pg/ml

5560.23 ± 1833.64

2236.66 ± 914.89

 < 0.001

  1. Data are number (%) and mean ± SD
  2. PsAF, persistent atrial fibrillation; PAF, paroxysmal atrial fibrillation; BMI, body mass index; bpm, beats per minute; CAD, coronary artery disease; HTN, hypertension; DM, diabetes mellitus; AF, atrial fibrillation; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; HbA1c, glycosylated hemoglobin; LDL, low density lipoprotein. BNP, brain natriuretic peptide; ACEI, angiotensin-converting enzyme inhibitor; ARB, agiotensin Receptor Blocker; TGF-β1, Transforming growth factor-beta 1